U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment: description was created based on several sources, including: http://www.drugbank.ca/drugs/DB01135

Doxacurium chloride (formerly recognized as BW938U80 or BW A938U) is a neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia for endotracheal intubation or to facilitate mechanical ventilation. Unlike a number of other related skeletal muscle relaxants, it is rarely used adjunctively to facilitate endotracheal intubation. Doxacurium chloride is a mixture of three trans, trans stereoisomers, a dl pair [(1R,1'R ,2S,2'S ) and (1S,1'S ,2R,2'R )] and a meso form (1R,1'S,2S,2'R). NUROMAX binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine.

Originator

Curator's Comment: synthesized by Mary M. Jackson and James C. Wisowaty, PhD (both chemists within the Chemical Development Laboratories at Burroughs Wellcome Co., Research Triangle Park, NC) in collaboration with John J. Savarese MD (who at the time was an anesthesiologist in the Dept. of Anesthesia, Harvard Medical School at the Massachusetts General Hospital, Boston, MA).

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
NUROMAX

Approved Use

NUROMAX is a long-acting neuromuscular blocking agent, indicated to provide skeletal muscle relaxation as an adjunct to general anesthesia, for endotracheal intubation or to facilitate mechanical ventilation.

Launch Date

6.7849919E11
Preventing
NUROMAX

Approved Use

NUROMAX is a long-acting neuromuscular blocking agent, indicated to provide skeletal muscle relaxation as an adjunct to general anesthesia, for endotracheal intubation or to facilitate mechanical ventilation.

Launch Date

6.7849919E11
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

adults: An initial NUROMAX dose of 0.08 mg/kg (3 × ED95) should be reserved for instances in which a need for very prolonged neuromuscular block is anticipated. Children: When administered during halothane anesthesia, an initial dose of 0.03 mg/kg (ED95) produces maximum neuromuscular block in about 7 minutes (range: 5 to 11) and clinically effective block for an average of 30 minutes (range: 12 to 54).
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Name Type Language
DOXACURIUM
VANDF   WHO-DD  
Common Name English
DOXACURIUM ION
Common Name English
DOXACURIUM [VANDF]
Common Name English
Doxacurium [WHO-DD]
Common Name English
DOXACURIUM CATION
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66886
Created by admin on Fri Dec 15 16:28:30 UTC 2023 , Edited by admin on Fri Dec 15 16:28:30 UTC 2023
WHO-ATC M03AC07
Created by admin on Fri Dec 15 16:28:29 UTC 2023 , Edited by admin on Fri Dec 15 16:28:29 UTC 2023
Code System Code Type Description
NCI_THESAURUS
C81000
Created by admin on Fri Dec 15 16:28:30 UTC 2023 , Edited by admin on Fri Dec 15 16:28:30 UTC 2023
PRIMARY
EVMPD
SUB01822MIG
Created by admin on Fri Dec 15 16:28:29 UTC 2023 , Edited by admin on Fri Dec 15 16:28:29 UTC 2023
PRIMARY
SMS_ID
100000087526
Created by admin on Fri Dec 15 16:28:30 UTC 2023 , Edited by admin on Fri Dec 15 16:28:30 UTC 2023
PRIMARY
MESH
C049429
Created by admin on Fri Dec 15 16:28:29 UTC 2023 , Edited by admin on Fri Dec 15 16:28:29 UTC 2023
PRIMARY
DRUG BANK
DB01135
Created by admin on Fri Dec 15 16:28:29 UTC 2023 , Edited by admin on Fri Dec 15 16:28:29 UTC 2023
PRIMARY
FDA UNII
P40015Y3WW
Created by admin on Fri Dec 15 16:28:29 UTC 2023 , Edited by admin on Fri Dec 15 16:28:29 UTC 2023
PRIMARY
CAS
106791-39-3
Created by admin on Fri Dec 15 16:28:29 UTC 2023 , Edited by admin on Fri Dec 15 16:28:29 UTC 2023
PRIMARY
DRUG CENTRAL
2974
Created by admin on Fri Dec 15 16:28:29 UTC 2023 , Edited by admin on Fri Dec 15 16:28:29 UTC 2023
PRIMARY
CHEBI
4706
Created by admin on Fri Dec 15 16:28:29 UTC 2023 , Edited by admin on Fri Dec 15 16:28:29 UTC 2023
PRIMARY
RXCUI
23651
Created by admin on Fri Dec 15 16:28:30 UTC 2023 , Edited by admin on Fri Dec 15 16:28:30 UTC 2023
PRIMARY RxNorm
WIKIPEDIA
Doxacurium
Created by admin on Fri Dec 15 16:28:30 UTC 2023 , Edited by admin on Fri Dec 15 16:28:30 UTC 2023
PRIMARY
All of the following components must be present:
Definition References